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1. Introduction 
Thyroid diseases are the most common endocrinopathies. In the Czech Republic they make 
up 80 to 90% workload of the endocrine centers. Thyroid diseases requiring treatment or at 
least follow up affect at least 5% of our population, for women middle-aged and older 10 to 
15%. 
In some thyroid diseases radioiodine 131I has been used for treatment.  
Hypothyroidism arises most often in the Czech Republic on the basis of chronic 
autoimmune thyroiditis, hypothyroidism is relatively common as artificial - after surgical or 
radioiodine therapy (RAIT) of various diseases of the thyroid gland. 
2. Hyperthyroidism 
In hyperthyroidism three major treatment modalities are currently available: antithyroid 
drugs, radioiodine and surgery, each of  which presents advantages and restrictions (Surk et 
al.,1990). RAIT is considered as the most comfortable and economical approach of 
hyperthyroidism treatment caused by Graves´ disease or toxic nodular goiter. Such 
treatment is indicated in patients with/or without functional autonomy to normalize 
thyroid function, and to reduce thyroid volume (Meier et al., 2002). 
The therapeutic use of radioiodine to treat hyperthyroidism from Grave's disease was first 
reported by Saul Hertz in 1941. Hertz administered produced a I-130 - I-131 mixture as a 
therapeutic dose to the first human patient with Graves’  disease at Massachusetts General 
Hospital. This was the first successful treatment of humans with an artificially produced 
radioactive material. Gradually a series of 29 patients were treated and documented 
(http://en.wikipedia.org/wiki/Saul_Hertz#cite_note-10). The Journal of the American 
Medical Association published in May 1946 the  paper with results of  a five year follow up 
study of the 29 patients and documented the successful treatment and safety of radioactive 
iodine for the treatment of hyperthyroidism. The follow-up study firmly launched the use of 
RAIT as a standard treatment for Graves´ disease (Hertz & Roberts, 1946). 
RAIT is applied mostly in hyperthyroid adults. However, it has recently gained appreciation 
also in children (Brown, 2009). In children radioiodine treatment should be considered in 
recurrent toxic goiter and in cases of ineffective thyrostatic drugs (Cooper, 2003). RAIT of 
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Graves’ disease was introduced 70 years ago, and it is estimated that more than one million 
individuals have been treated with 131I for hyperthyroidism (Chapman, 1983). The use of 
radioactive iodine has been detailed for more than 1200 children (Rivkees et al., 1998). 
Patients as young as 1 yr of age have been treated with 131I with excellent outcomes (Rivkees 
et al.1998). Some studies have reported remission rates that exceed 95%, with very rare 
complications (Levy et al., 1988, Read et al., 2004, Rivkees et al.1998). Properly administered 
radioactive iodine remains an ideal form of treatment for Graves’ disease in the pediatric 
population and it is an effective cure for Graves’ disease which is associated with few acute 
side effects (Rivkees & Dinauer 2007). When radioiodine is used at appropriate doses, there 
is a very high cure rate without increased risks of thyroid cancer or genetic damage 
(Rivkees, 2001). Also data of Moll & Patel (Moll & Patel, 1997) from nearly 8 years 
experience with 131I therapy support consideration of RAIT  within 3 to 6 months of 
diagnosis of pediatric Graves´ disease as an effective, efficient, and probably safe alternative 
approach to the traditional antithyroid therapy of Graves´ disease in children. 
For 70 years  radioidine has been used to treat most cases of Graves´ disease and thyroid 
autonomies. The thyroid gland utilizes iodine for the synthesis of thyroid hormones. The 
cells do not differentiate between stable and radioactive iodine. If radioactive iodine is 
administered, it is trapped and then organified by thyroid follicular cells like nonradioactive 
iodine. The therapeutic effects of  131I sodium iodide are due to the emission of ionizing 
radiation from the decaying radionuclide. The therapy is based on short-range beta 
radiation from radioactive 131I. The beta particles, due to their high mean energy (190 keV, 
with typical beta-decay spectra present) have a tissue penetration of 0.6 to 2 mm (Skugor, 
2006). Radioiodine administration should be preceded by pharmacological normalization of 
fT4 and fT3 levels, beacause post-radiation thyrocyte destruction and thyroid hormone 
release can lead to hyperthyroidism exacerbation (Gurgul & Sowinski, 2011). In some cases 
it is possible to withdraw antithyroid drugs 10-14 days before radioiodine administration to 
restore appropiate iodine uptake. It is known that one of the cause of reduced 131I uptake 
and shortened effective half life is pre-treatment with antithyroid drugs (ATD), which may 
have an additional radio-protective effect. It can influence the outcome of 131I therapy (Sabri 
et al., 2001, Walter et al., 2002) with possibility a risk of treatment failure for lower delivered 
radioiodine doses to the target tissue (Dunkelmann et al., 2005). Tuttle et al. describe that 
antithyroid drug therapy has been associated with relative radioresistance and with a 
decrease in radioiodine therapy effectiveness (Tuttle et al., 1995).   A similar effect as longer 
discontinuation of ATD (10-14 days) can be obtained when ATD is discontinued 24 hours 
before 131I administration („bounce effect“) (Gurgul & Sowinski, 2011). But in severe 
hyperthyreoidism it is not possible to withdraw ATD for a long time, that is why 
discontinuation of ATD starting two or three days before 131I is now widely accepted 
(Walter et al., 2002). 2-day ATD withdrawal prior to radioiodine administration sufficiently 
increases the radioiodine uptake and does not exacerbate hyperthyroidism compared to 7-
day withdrawal in Graves´ disease patients. There is not significant diference in RAIT 
outcomes between 2-day and 7-day groups. In order to prevent serum thyroid hormone 
increase after ATD withdrawal and RAIT, a 2-day ATD withdrawal period before RAIT may 
be useful for high-risk patients such as the elderly and patients with cardiac complications 
(Kubota et al., 2006). Pretreatment with propylthiouracil but not methimazole, discontinued 
even 15 days before radioiodine administration, reduces the rate of success of 131I therapy. 
Propylthiouracil pretreatment and large goiters are related to failure of radioiodine therapy. 
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Propylthiouracil should be avoided if radioiodine is considered in the management of 
hyperthyroid patients with Graves´ disease (Santos et al., 2004). Bonnema et al. (Bonnema et 
al., 2004) have shown, in a randomized set-up, that propylthiouracil treatment before 131I 
therapy for hyperthyroid diseases approximately halves the cure rate at 1 year and that after 
classification the outcome into two categories, cured (euthyroidism or hypothyroidism) or 
not cured (recurrence), the treatment failure rate in patients with toxic nodular goiter was 
approximately 4 times as high in the propylthiouracil pretreatment group as in the group 
without propylthiouracil pretreatment, whereas the diference among patients with Graves’ 
disease was less obvious. Andrade et al. have demonstrated  that thyroid hormone levels 
stabilize or decrease after RAIT in patients with Graves’ hyperthyroidism who are not 
pretreated with ATD (Andrade et al., 1999). Andrade et al. proved that short term increase 
in thyroid hormone levels in patients with Graves’ hyperthyroidism  receiving RAIT occurs 
mainly as a result of discontinuing antithyroid drug therapy. Among patients who received 
RAIT without pretreatment, serum thyroid hormone levels did not change or decreased in 
the 30-day interval after radioiodine administration. They postulated that RAIT without 
pretreatment with ATD can be safely prescribed (Andrade et al., 1999). Burch et al. (Burch et 
al., 2001) concluded that pretreatment with ATD does not protect against worsening 
thyrotoxicosis after radioiodine, but this pretreatment provides a measure of protection by 
establishing lower baseline values should an exacerbation of thyrotoxicosis occur. The 
findings support the recommendation that most patients with Graves’ disease do not 
require antithyroid drug pretreatment before receiving radioiodine. 
In benign conditions such as Graves´ disease, division of some metabolically active cells is 
prevented by the effect of the ionizing radiation of radioiodine. Cell death is another 
mechanism activated when the cells are exposed to high levels of radiation, for example in 
autonomous adenoma, where the suppressed normal thyroid tissue is essentially spared 
with delivery of a very high concentration to the cells of the autonomous adenoma (toxic 
nodule). Cell death is followed by replacement with connective tissue, which may lead to 
hypothyroidism, depending on the number of cells destroyed and replaced by fibrous 
nonfunctioning tissue. Since 90% of the radiation effects of 131I are due to beta radiation, 
which has a short range in tissue, the extrathyroid radiation, and consequently the side 
effects, are minimal. 
The potential risk after radioiodine therapy of hyperthyroidism that is most extensively 
discussed in the literature is cancer induction  (Lacko et al., 2001, Reiners, 1997, Vlček & 
Neumann, 2002). Since the 1980s, large-scale, long-term (15–17 years) follow-up studies of 
cancer risk in patients treated with radioiodine for hyperthyroidism have been reported 
(Franklyn et al., 1999, Goldman et al., 1988, Hoffman et al., 1982, Holm et al., 1991) with 
conflicting results. The first 2 longterm studies were continuations of the Cooperative 
Thyrotoxicosis Therapy Follow-up Study (Hoffman et al., 1982, Goldman et al., 1988). 
Hoffman et al. (Hoffman et al., 1982) reported no difference between 1005 women treated 
with radioactive iodine and 2141 women treated with surgery for hyperthyroidism in 
total cancer incidence, breast cancer, or leukemia. Although based on a small number of 
cases, an elevated risk of cancer was observed in the thyroid gland and other organs that 
concentrate radioiodine (salivary glands, digestive tract, kidney, and bladder) (Hoffman 
et al., 1982). In a study of Goldman et al. (Goldman et al., 1988) the cancer incidence of 
1762 hyperthyroid women (80% treated with radioactive iodine) did not differ from that 
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of US white women. In a large population-based study of 10552 Swedish patients who 
received RAIT for hyperthyroidism, significantly elevated overall cancer incidence was 
observed compared with the Swedish population (Holm et al., 1991). Among 10-year 
survivors, significantly elevated risks were seen for cancers of the stomach, brain, and 
kidney ( Holm et al., 1991). In a population-based study of 7417 patients treated with 
radioiodine for hyperthyroidism in Birmingham (UK), the overall cancer incidence and 
mortality decreased, but the incidence and mortality of cancers of the small bowel and the 
thyroid gland were increased compared with expected rates (Franklyn et al., 1999). 
According to the American Cooperative Thyrotoxicosis Therapy Follow-up Study (Ron et 
al., 1998) RAIT of hyperthyroidism was linked to a slightly increased risk for thyroid 
cancer. Metso proved that cancer incidence, especially cancer of the stomach, kidney, and 
breast, was higher in patients treated with radioiodine for hyperthyroidism (Metso et al., 
2007).  On the other hand, a Swedish follow-up study did not reveal any increased risk of 
thyroid cancer (Holm et al., 1991). Although radioactive iodine is being used in 
progressively younger ages, it is not known if there is an age below which high-dose 131I 
therapy should be avoided. Risks of thyroid cancer after external irradiation are highest in 
children younger than 5 yr of age and progressively decline with advancing age (Boice, 
1998, 2006, Dolphin, 1968, Read et al., 2004). If there is residual thyroid tissue in young 
children after RAIT, there is a theoretical risk of thyroid cancer. It may therefore be 
prudent to avoid RAIT  in children younger than 5 years (Rivkees & Dinauer, 2007). In 
addition to thyroid cancer, potential influences of 131I therapy on other cancers need to be 
considered. Follow-up from the large cohort of the Cooperative Thyrotoxicosis Therapy 
Follow-Up Study did not find increased risks of leukemia in the 131I -treated group, as 
compared with the drug- and surgery-treated groups (Saenger et al., 1968). No increase in 
overall cancer mortality was seen in the 131I-treated patients either (Ron et al., 1998). In 
one other study, excess thyroid cancer mortality after 131I therapy for Graves’ disease was 
observed during early, but not late, follow-up (Hall et al., 1992a). Yet this was related to 
increased cancer surveillance and detection, not 131I effects (Hall et al., 1992a). Edmonds 
and Smith (Edmonds & Smith, 1986) reported a small but significant excess of incidence 
and mortality of leukemia in 258 patients treated with high-activity radioiodine for 
thyroid cancer (2960 MBq to 5550 MBq). However, no increased risk for malignancies of 
the hematopoietic system was found in the study of Metso et al. (Metso et al., 2007), which 
is in the agreement with earlier studies on patients treated with radioactive iodine (370 
MBq to 555 MBq) for hyperthyroidism (Franklyn et al., 1999, Hall et al., 1992b, Hoffman et 
al., 1982, Holm et al., 1991). No increase in the risk of thyroid malignancies has been 
observed in patients treated with radioiodine for hyperthyroidism in most of the 
published long-term follow-up studies (Augusti et al., 2000, Goldman et al., 1988, Holm et 
al., 1991). 
Several factors affect the therapeutic activity  to be administered to patients suffering from 
hyperthyroidism including factors related to gland itself, particularly its size, the level of 
radioiodine uptake, the rate of iodine turnover in the gland (measured by the effective half-
life), scintigraphic findings of uniform or nonuniform uptake, and whether nodules are 
present. The dose (in Gray) is dependent on how the nuclear medicine physician defines the 
goals of therapy. If the control of hyperthyroidism is the most important consideration, the 
total activity (in megabecquerels - MBq) or the dose per gram of estimated thyroid tissue 
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weight will be higher than when the physician is trying to avoid or delay hypothyroidism. 
In our department we use individually calculated therapeutic radioiodine activity (in MBq) 
using Marinelli´s formula (Marinelli et al., 1948): 
Absorbed Dose * Volume
Activity = K *
Max. Uptake (%) * eff. Half - life
 
K = 24,94; absorbed dose in Gray-Gy; volume of target thyroid tissue in ml or weight in g;  
effective half time in days 
We calculate it from a formula referring to thyroid volume, radioiodine uptake and its half-
life time. But it is difficult to determine the radioiodine sensitivity of thyroid tissue which 
depends on the structure of normal sized thyroid or goiter and is individually variable. This 
parameter cannot be estimated and that is why it is difficult to predict the effectiveness of 
RAIT. While waiting for the effects of the RAIT, thyroid function should be controlled 
regularly. If hyperthyreoidism is still present 4-6 months after 131I administration, the 
therapy can be repeated. However, in some patients the therapeutic effects can be observed 
up to 12 months later (Cooper, 2003, Gurgul & Sowinski, 2011, Nygaard et al., 1999b). In our 
opinion calculated radioiodine activity is advantageous and we prefer it in RAIT, but some 
authors prefer fixed activities (Leslie et al., 2003). 
2.1 Graves´ disease 
Thyroid scintigraphy shows uniform uptake throughout thyroid gland (Fig. 1) or varying 
degrees of nonuniform uptake. 
This nonuniformity is related predominantly to different stages of involution of the disease 
with variable amounts of fibrosis based on the duration of the disease.  Infiltration of 
extraocular muscles by an inflammatory reaction consisting predominantly of lymphocytes 
is the main pathological feature of ophtalmopathy. These lymphocytes are sensitized to 
antigens common to the orbital muscles and thyroid gland. 
Indications for RAIT include recurrent hyperthyroidism after thyrostatic treatment or 
thyroidectomy. It is also recommended in patients with concomitant severe diseases 
(Gurgul & Sowinski, 2011). The first activity of 131I is sufficient in 70% of patients with 
Graves´ disease (Cooper, 2003). The rest requires repeated RAIT.  
Absolute contraindications to 131I therapy is pregnancy and breastfeeding (Sisson et al., 
2011). 
Although there is general consensus that radioiodine is a safe and effective treatment for 
Graves’ hyperthyroidism, debate remains in terms of the optimal method for calculating the 
activity (in MBq) and even what the criteria should be for defining optimal. Sustained 
euthyroidism would clearly be the most desirable outcome, but this appears to be a futile 
objective, because high rates of cumulative hypothyroidism are reported in most series. 
Findings of Leslie et al. (Leslie et al., 2003) confirm this result, with the vast majority 
developing permanent hypothyroidism and very few with euthyroidism. Therefore, the 
objective of eradicating hyperthyroidism at the lowest effective radioiodine dose may well 
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be the preferred strategy. This has led some groups to suggest a larger initial radioiodine 
dose (in Gy) and activity (in MBq) to minimize the need for retreatment and the morbidity 
and medical costs associated with ineffective primary treatment. Alternatively, others favor 
a low activity approach (185 MBq), at least for those with mild disease and without 
complications (Nordyke & Gilbert, 1991). Allahabadia et al. (Allahabadia et al., 2001), who 
use fixed therapetic activity reported these results: patients given a single activity of 370 
MBq had a higher cure rate than those given 185 MBq, but an increase in hypothyroidism 
incidence at 1 year. There was no difference in cure rate between the groups with Graves’ 
disease and those with toxic nodular goiter, but Graves’ patients had a higher incidence of 
hypothyroidism. Males had a lower cure rate than females, whereas younger patients (<40 
years) had a lower cure rate than patients over 40 years old (Allahabadia et al., 2001). 
 
Fig. 1. Thyroid scintigraphy – diffuse goiter in Graves´ disease 
2.2 Toxic nodular goiter (Plummer´s disease) 
It means hyperthyroidism in glands with both single and multiple toxic nodules. The toxic 
nodular goiter contains nodules that are not hyperactive. 
Therapy of Graves´ disease and toxic nodular goiter can be conservative with drugs, 
surgical and by radioiodine. Surgery is connected with higher risk, RAIT is indicated most 
often. RAIT in the world today is the most common and the least expensive therapy. It is 
indicated mainly for failure of conservative treatment, also in the organ complications, 
especially circulation (atrial fibrillation, circulatory failure), or where the operation is 
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contraindicated for other reasons. In toxic nodular goiter radioiodine is used mostly in 
recurrent goiter. This therapy reduces thyroid volume by approximately 40%. The efficiency 
of RAIT is estimated at 70% (Nygaard et al., 1999b). 
Late complication after radioiodine therapy is the development of transient or permanent 
hypothyroidism. The early transient hypothyroidism is that which arose within six months 
of treatment with radioiodine. It is a block of hormonogenesis after radioiodine. It is caused 
by an immunological mechanism. 
As the early permanent hypothyroidism we consider a steady increase of TSH levels within 
1 year after therapeutic application of radioiodine. In the permanent hypothyroidism the 
failure of hormonogenesis is involved in addition to immunological processes, damage of 
the follicular cell nuclei, which leads to accelerated aging and cell death. Hypothyroidism 
develops after radioiodine therapy like postoperatively in patients with hyperthyroidism. 
Hypothyroidism after RAIT gradually increases with time, several years after this therapy. It 
is detected at several tens of percent of such treated patients. Hypothyroidism develops in 
10-30% of patients treated with radioiodine, especially due to Graves´ disease (Cooper, 
2003). However, it cannot be considered as a side-effect of such therapy. Hypothyroidism 
ocurrence is estimated at 1-2% per year (Cooper, 2003). Despite the numerous attempts to 
design dosage schedules aiming at euthyroidism, hypothyroidism occurs in the majority of 
patients throughout life (Pauwels et al., 2000). 
Hypothyroidism occurs at a linear rate on a permanent basis (Staffurth, 1987, Taylor et al., 
1984). Besides permanent hypothyroidism, transient hypothyroidism may be seen in 
patients 2-5 months (or in the first year) after RAIT with spontaneous recovery in the 
following months (Connell et al., 1983,  Dorfman et al., 1977). 
 131I activities are typically calculated to deliver the desired amount of radiation based on 
gland size and radioactive iodine uptake (Quimby et al., 1970). Some centers administer to 
all patients the same fixed activity of 131I with excellent outcome (Nebesio et al., 2002). When 
children are treated with the dose more than 200–250 Gy/g, hypothyroidism is achieved in 
nearly 95% of patients (Rivkees & Cornelius, 2003). But in our opinion these doses per gram 
are too high. Gland size also influences treatment outcome, as higher doses of 131I are 
needed to induce hypothyroidism when large glands are present (up to 60 g) (Rivkees & 
Cornelius, 2003). When thyroid size exceeds 80 g, remission rates after 131I therapy are poor 
(Peters et al., 1996). Thus, surgery is preferred when thyroid gland size is large (>60–80 g). 
Hamburger reported the largest series of pediatric patients with Graves´ disease in which 
131I therapy resulted in relatively uncomplicated clinical courses, except for hypothyroidism 
requiring lifelong thyroid hormone replacement in 89% (Hamburger, 1985). 
Several studies have attempted to determine the optimal activity of radioiodine for curing 
hyperthyroidism, while avoiding the development of permanent hypothyroidism.  
Regimens used have included low activity 80 MBq (Franklyn et al., 1991, Lowdell et al., 
1985, Nordyke & Gilbert 1991), various fixed activity (185, 370, and 555 MBq) (Franklyn et 
al., 1991, Jarlov et al., 1995, Nordyke & Gilbert, 1991, Watson et al., 1988), and activities 
calculated on the basis of thyroid size, the uptake of radioiodine, or the turnover of 
radioiodine (Franklyn et al., 1991,  Jarlov et al., 1995, Sridama et al., 1984). Most dosimetric 
methods have the benefit of including a measure of thyroid size in their formulas, thereby 
administering a dose of radioiodine proportional to size of the gland and theoretically 
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increasing the probability of cure, because this has been considered to be an important 
prognostic factor for success after RAIT. In addition, the use of isotope uptake 
measurements, as part of the activity calculation protocol, can confirm the absence of 
thyroiditis and identify patients with values at the extreme ends of the reference range of 
isotope uptake or turnover, which may predict failure of RAIT (Kaplan et al., 1998). Despite 
these potential benefits of calculated acitivities, several studies have failed to demonstrate 
improvements in cure rate over fixed activities (Catargi et al., 1999, Jarlov et al., 1995, Peters 
et al., 1995). Furthermore, there is little evidence that using a calculated activity has any 
advantage over a fixed-activity regimen, in terms of preventing hypothyroidism (Turner et 
al., 1985, Sridama et al., 1984), so many centers and clinicians prefer the use of a fixed-
activity regimen (Hedley et al., 1992, Franklyn, 1994). 
Although low fixed activities (185 MBq) are associated with a reduced early incidence of 
hypothyroidism, they often result in unacceptably low cure rates. Moreover, the 
development of long-term hypothyroidism seems to be inevitable, irrespective of the 
amount of radioiodine administered, with an annual incidence of 2–3% many years after 
therapy (Franklyn et al., 1991, Hennemann et al., 1986). Some clinicians now prefer to give a 
large ablative activity (555 MBq and upwards), which results in early hypothyroidism, so 
that the need for long-term follow-up of thyroid function in euthyroid patients is obviated. 
2.3 Endocrine orbitopathy 
Very advanced endocrine orbitopathy has a significant symptomatology. Therapy of 
endocrine orbitopathy complicated thyreotoxicosis is done with the cooperation with 
ocularist. RAIT may increase the inflammatory process and exacerbate the ophtalmological 
symptoms. This is due to radiation thyroiditis, which releases thyroid antigens and 
stimulates antithyroid antibody production. Therefore, in these patients, high doses of 131I 
are recommended to assure complete thyroid tissue destruction, especially when high 
thyroid stimulating hormone receptor antibody (TRAb) levels are observed. The elimination 
of thyroid antigens and lymphocytes infiltration may reduce the autoimmunological process 
that is responsible for hyperthyroidism and endocrine orbitopathy (Gurgul & Sowinski, 
2011). After calming of thyrotoxicosis we must think of definitive therapy - thyroidectomy 
followed by ablative radioiodine therapy. Of course then the patient is without the thyroid 
gland, with rapid development of hypothyroidism. The hormonal replacement therapy is 
necessary. 
2.4 Thyroid autonomies 
Autonomously functioning thyroid tissue is characterized by the ability to function without 
TSH. Neither the antibodies nor TSH is involved. The group of follicular cells just continues 
autonomously to produce excess amount of thyroid hormones. For clinical diagnosis, 
radioiodine or 99mTc-pertechnetate imaging of the thyroid gland is performed. Normally the 
scan would show increased radionuclide uptake by the autonomous thyroid area (with or 
without nodule) compared with surrounding normal thyroid tissue. Histological 
examinations of tissue corresponding to scintigraphically autonomous areas show different 
architectural patterns and histological features of follicular cells compared with normal 
quiescent tissue (Kraft, 2006). 
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The main cause of functional autonomies of the thyroid is iodine deficiency. A higher 
prevalence of functional autonomies in thyroid tissue have been described in areas with an 
endemic iodine deficiency (Belfore et al., 1983, Guglmann et al., 1995), the prevalence in 
countries replete with iodine is below (Hamburger, 1980). 
The main pathologic attribute of thyroid functional autonomies is the loss of regulation in 
the axis of hypothalamus-hypophysis-thyroid. 
The histopathology of goiter varies with etiology and age of the goiter. Initially, uniform 
follicular epithelial hyperplasia (diffuse goiter) is present with an increase in thyroid mass. 
As the disorder persists, the thyroid architecture loses uniformity, with the development of 
areas of involution and fibrosis interspersed with areas of focal hyperplasia. This process 
results in multiple nodules. On scintigraphy, some nodules are “hot,” with a high 
radionuclide uptake (in the end autonomous), or “cold,” with a low radionuclide uptake, 
compared with the normal thyroid tissue. The development of nodules correlates with the 
progression of functional autonomy and a reduction in TSH levels. Clinically, the natural 
history of a nontoxic goiter is growth, nodule production, and functional autonomy, 
resulting in thyrotoxicosis in a minority of patients (Lee & Ananthakrishnan 
http://www.emedicine.com/med/TOPIC919). 
Functional autonomous tissue can present as an autonomous adenoma with nodule (Fig. 2),  
multifocal functional autonomy in multinodular goiter (MFA) (Fig. 3), or unifocal functional 
autonomy in thyroid glands without nodules (UFA) or diffuse functional autonomy (DFA). 
 
Fig. 2. Thyroid scintigraphy - autonomous adenoma before (on the left) and after (on the 
right) successful RAIT 
Thyroid adenomas (and most nodules in goiters), even if morphologically heterogenous, are 
true benign tumors (Studer & Derwahl, 1995). 
For the diagnostics of thyroid fuctional autonomy and the evaluation of the radioiodine 
therapeutic effect of functional autonomies, a thyroid scintigraphy is the basic and necessary 
procedure. Decisions concerning the definitive treatment of thyroid autonomy should take 
into account previous episodes of hyperthyroidism, objective parameters of risk 
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stratification in euthyroid patients, concomitant diseases, and the probability of future 
iodine exposure. 
 
Fig. 3. Thyroid scintigraphy - multifocal functional autonomy in multinodular goiter before 
(on the left) and after (on the right) successful RAIT 
Autonomous adenoma in single thyroid nodule or unifocal or multifocal thyroid 
autonomies can secrete sufficient thyroid hormones to cause hyperthyroidism.  In 
autonomous adenoma palpable nodule can suppress paranodular tissue (decompensated 
adenoma) with suppressed TSH with normal or higher fT3 and/or fT4 or the function of the 
surrounding tissue  is preserved (compensated adenoma). Initial thyreosuppressive 
conservative therapy cannot have  permanent effect and we cannot expect remission and it 
should be treated with radioiodine or operate. 
Patients with autonomy who develop hyperthyroidism spontaneously or after iodine excess 
carry a high risk of recurrence, ranging from 55% up to 81% (Voth et al., 1990). There is 
general agreement that if hyperthyroidism occurs or has occurred in autonomy, definitive 
treatment is indicated. RAIT is indicated in patients with functionally relevant autonomy to 
normalize thyroid function, to remove functional autonomy, and to reduce thyroid volume 
(Meier et al., 2002). 
Radioiodine treatment should be preferred over surgery in patients with smaller goiters 
(volume <100 ml), the absence of cold nodules or cysts, or the lack of suspicion for 
malignancy, as well as in those who have undergone previous surgery or would be at 
increased risk from a surgical intervention. On the other hand, surgery should be preferred 
in all patients who do not meet these criteria, as well as in the presence of compression 
symptoms and when there is a need for an immediate therapeutic effect. The risk of relapse 
on medical treatment with ATD alone is very high, exceeding 80% and long-term 
antithyroid treatment is not safe in elderly patients, mainly because of poor compliance or a 
dose reduction by inexperienced physicians. Ablative treatment should be preferred in 
patients with overt hyperthyroidism owing to functional autonomy. RAIT represents the 
most comfortable and economic approach (cost of radioiodine and short hospitalization is 
lower than surgery or long-term conservative therapy). The aim of RAIT in autonomy is the 
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destruction of autonomous tissue with restoration of euthyroidism. Some groups have 
successfully used standard activities without any activity calculation. We advocate 
individual pretherapeutic dosimetry to determine the activity necessary to achieve a 
targeted radiation dose in autonomously functioning tissue. If the elimination of 
hyperthyroidism in patients with autonomy is achieved, RAIT can be considered successful. 
The normalization of serum TSH has been proposed as a criterion in the evaluation of a 
post-therapeutic outcome. Serum TSH >0,5 mU/l excludes autonomous thyroid function 
with a probability of 88% in an iodine deficiency area (Becker et al., 1992). Therefore, the 
normalization of this parameter following radionuclide treatment usually indicates a 
favorable result. Long-term suppressed serum TSH after 131I, on the other hand, has a low 
predictive potential, as it is often decreased for a prolonged period, despite therapeutic 
success (Seeger et al., 1995). 
In our great group of 868 patients with unifocal and multifocal functional autonomy, and 
disseminated functional autonomy who received at least one treatment of radioiodine side-
effects were minimal. Postradiation hypothyroidism was diagnosed in 38 patients (4,4%). 
Such a low incidence of hypothyroidism can be influenced by these factors: 1. A very low 
number of patients had previous treatment with methimazole, which is associated with a 
faster progression toward hypothyroidism (Ceccarelli et al., 2005); 2. Before 131I therapy in 
patients with functional autonomy, the degree of nonautonomous thyroid tissue 
suppression was high, and this tissue was not influenced by radioiodine beta rays 
(radioiodine is absorbed only in autonomous nodule or tissue, therefore it destroys only this 
area and does not damage the remaining thyroid tissue); 3. follow-up of our patients was 2 
years long, and certainly later, the number of hypothyroid patients can (but maybe not) 
increase (Ceccarelli et al., 2005). In the literature, the incidence of hypothyrodism after RAIT  
for functional autonomy of the thyroid is described in 10%–20% cases (Reiners & Schneider, 
2002) and even in 60% (Ceccarelli et al., 2005). 4. pretherapeutic dosimetry with a treatment by 
means of individually calculated 131I  activity  (Kraft & Stepien, 2007). Generally, in thyroid 
autonomies, focused radioiodine absorption only or almost only in autonomous areas results 
in selective destruction of these areas. Low TSH levels decreases radioiodine uptake in 
surrounding tissue, which additionally protects healthy thyroidal tissue. Therefore, the 
effectiveness of RAIT in thyroid autonomies is very high and the risk of hypothyroidism is low 
(Gurgul & Sowinski, 2011). This is in contrast to the situation for example in RAIT of Graves´ 
disease and toxic nodular goiter. Non-suppressed serum TSH before 131I therapy has been 
mentioned as a risk factor for development of hypothyroidism (Farrari et al., 1996). Nygaard 
(Nygaard et al., 1999a) had a cure-rate of 75% within 3 months when treating autonomous 
solitary thyroid nodules with 131I  in 62 patients. The thyroid volume was reduced by 35% 
within 3 months and 45% after 2 years. Side effects  were few and consist of hypothyroidism in 
8% with a median follow-up of 5 years (Nygaard et al., 1999a). 
3. Euthyroid goiter 
Small eufunctional goiter usually does not carry any trouble. The growth of goiter gradually 
creates local problems and in advanced stages we can objectively find the compression of 
the trachea and esophagus, abnormal innervation of the larynx, possibly obturation of the 
upper aperture. On scintigraphy the diffuse goiter accumulates homogeneously, in nodular 
goiter some areas accumulate with reduced and often with increased activity (Fig.4). 
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Fig. 4. Thyroid scintigraphy – nodular goiter with normal function and mechanical 
syndrome 
Goiter with mechanical syndrome is a disease that has to be solved urgently and radically 
(Fig.5). In the first place surgery comes. If thyroidectomy is contraindicated, the use of RAIT 
is appropriate.  
 
Fig. 5. Thyroid scintigraphy – retrostrernal goiter after thyroidectomy with mechanical 
syndrome 
After this treatment, postradiation hypothyroidism is a common finding with need to use 
replacement therapy of thyroid hormones. 
4. Differentiated Thyroid Cancers (DTC) 
Radioiodine is the mainstay of therapy for residual, recurrent, and metastatic thyroid cancer 
that takes up iodine and cannot be resected. About 90% or more of thyroid carcinomas are 
well differentiated (papillary or follicular types), which take up iodine and accordingly can 
be successfully treated with 131I. The therapeutic effects on differentiated thyroid cancer is 
based on destruction of cells by high dose of administered radioiodine. RAIT is defined as 
the systemic administration of 131I - sodium or potassium iodide for selective irradiation of 
thyroid remnants, microscopic DTC or other nonresectable or incompletely resectable DTC, 
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or both purposes. Based on the primary goal of the RAIT, there are two main forms of the 
procedure (Luster et al., 2008). The first form, radioiodine ablation, is a post-surgical 
adjuvant modality. It seeks to eliminate thyroid remnants to increase the sensitivity and 
specificity of follow-up testing for DTC persistence or recurrence, namely, of assays of 
serum thyroglobulin (Tg) as a tumour marker and of diagnostic whole-body scintigraphy 
(dxWBS) (Fig. 6). Ablation also allows sensitive “post-therapy” whole-body scintigraphy 
(rxWBS) (Fig. 7) that may detect previously occult metastases (Dietlein et al., 2007) and 
serves to treat any microscopic tumour deposits. 
Ablation, therefore, may reduce long-term morbidity and possibly, mortality (Dietlein et al., 
2007, Sawka et al., 2004, Pacini et al., 2005). Ablation success is evaluated 6–12 months after 
the ablation procedure. The second form of RAIT, radioiodine treatment of nonresectable or 
incompletely resectable lesions, e.g. microscopic disease, macroscopic local tumour or 
lymph node or distant metastases, is performed as curative or paliative therapy either as a 
component of primary treatment of DTC or to address persistent or recurrent disease 
(Luster et al., 2008). Radioiodine ablation after total or near-total thyroidectomy is a 
standard procedure in patients with DTC. When radioiodine uptake is scintigraphically 
proven before or after RAIT, then RAIT of nonresectable or incompletely resectable tumour, 
e.g. local recurrences, lymph node metastases or disseminated iodineavid lung metastases 
or other distant lesions, has shown to be effective in eradicating disease, slowing disease 
progression or providing symptomatic relief (Durante et al., 2006). Decision on whether or 
not to give RAIT with the intention of cure or palliation should be individualised to the 
patient and should consider several factors, among others also the patient health status — 
inability to tolerate surgery or other potential therapeutic interventions, e.g. chemotherapy. 
  
Fig. 6. Diagnostic whole-body scintigraphy - normal finding  
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Fig. 7. Post-therapy whole-body scintigraphy. Multiple lung metastases which accumulate 
radioiodine  
It can make RAIT the preferred or the only therapeutic option; conversely, where use of 
recombinant human thyroid-stimulating hormone (rhTSH) is not economically feasible, 
inability to tolerate hypothyroidism could rule out RAIT. 
Absolute contraindications of RAIT is pregnancy and  breastfeeding (as in RAIT in 
hyperthyroidism). 
The effectiveness of RAIT depends on the patient’s serum TSH level being sufficiently 
elevated. A TSH level of ≥30 mU/l is believed to increase sodium iodine symporter (NIS) 
expression and thereby to optimise radioiodine uptake (Cooper et al., 2006). Such TSH 
elevation can be reached by waiting at least 3 weeks after thyroidectomy or 4–5 weeks after 
discontinuing treatment with levothyroxine (T4). Triiodothyronine (T3) may be substituted 
for T4 until 2 weeks before RAIT in an attempt to decrease the duration of hypothyroidism. 
When thyroid hormone is withheld, it should be initiated or resumed 2 days after 
radioiodine administration. Traditional thyroid hormone withdrawal  has the major 
drawback of causing weeks to months of hypothyroid symptoms in most patients (Duntas & 
Biondi, 2007, Luster et al., 2005, Dow et al., 1997, Schroeder et al., 2006). Such physical and 
psychological morbidity may include fatigue, depression, impaired ability to concentrate, 
sleep disturbance, weight gain, constipation, dry skin, hoarseness, puffy face or hands, 
cardiovascular abnormalities, impaired renal function and exacerbation of dyslipidemia 
(Billewicz et al., 1969, Botella-Carretero et al., 2003, 2004, 2005, 2006, Luster et al., 2005, 
Tagay et al., 2005). These manifestations in turn frequently significantly decrease patient 
quality of life, cause absenteeism from or impaired performance in work or study or lead to 
debilitating or even life-threatening worsening in psychological, cardiovascular, renal or 
other concomitant conditions (Borget et al., 2007, Dow et al., 1997, Duntas & Biondi, 2007, 
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Haugen et al., 1999, Ladenson et al., 1997,  Leclere et al., 2000, Luster et al., 2005, Nijhuis et 
al., 1999, Schroeder et al., 2006). 
An alternative to thyroid hormones withdrawal for attaining TSH elevation is rhTSH 
administration. In Europe and elsewhere, this drug has been approved for use in adults as 
preparation for serum Tg testing, dxWBS or both or for radioiodine ablation (Luster, 2006). 
Radiosensitivity of thyroid gland is relatively high. For destruction and ablation of normal 
thyroid gland is needed higher activity than for destruction of tumor tissue. 
 Because of the larger dose of radioiodine and the lower uptake by the tissue in thyroid 
cancer, more side effects can be seen, particularly transient sialoadenitis, than in the therapy 
of hyperthyroidism. The mortality of patients treated with less than total thyroidectomy and 
limited 131I treatment was found to be three to four times higher than that of patients treated 
with total thyroidectomy and RAIT to ablate known foci of radioiodine uptake. 
Thyroglobulin is the major tumour marker for thyroid cancer of the follicular epithelium. It 
is not only specific for tumour tissue but is also specific component of normal thyroid tissue. 
Since thyroglobulin is produced exclusively by thyroid tissue, only very small amounts can 
be found in the blood after thyroidectomy and ablative radioiodine therapy. Any post-
therapeutic elevation of its levels indicates either remnant of thyroid tissue, requiring 
further ablative therapy, or the presence of metastases or local recurrence. Following total or 
near-total thyroidectomy, TSH elevation reaches a maximum in 4-6 weeks. In the follow-up 
care, patients are maintained on suppressive doses of thyroid hormone. The goals of follow-
up after initial therapy are to maintain adequate levothyroxine (T4) therapy and to detect 
persistent or recurrent thyroid carcinoma. All patients with thyroid cancer must be treated 
with thyroid hormone after thyroidectomy for correction of surgically induced 
hypothyroidism and to suppress stimulated growth of persistent or recurrent thyroid cancer 
by reducing TSH levels. Thus thyroid hormone therapy ensures „replacement“ therapy, 
which corrects hypothyroidism, and „suppressive“ therapy, which inhibits TSH secretion. 
Thyroid cell proliferation and differentiation is mainly TSH dependent. Therefore TSH 
secretion must be inhibited by thyroid hormone therapy in all patients with differentiated 
thyroid cancers. Thyroid hormone is a basic principle that is included in the guidelines of 
thyroid cancer therapy. Before administration of radioiodine, thyroid homone therapy has 
to be interrupted for diagnosis or treatment. Radioiodine uptake, thyroglobulin synthesis 
and its secretion by thyroid cancer cells will be stimulated by increased TSH. Neoplastic as 
wel as normal thyroid cell differentiation depends on TSH. Accordingly, metastases take up 
radioiodine only if the patient is hypothyroid with high serum TSH levels, while no uptake 
is seen when the patient is on hormone suppressive therapy with low or undetectable serum 
TSH concentrations. Serum TSH level should be taken into account when interpreting the 
serum thyroglobulin value as the presence or absence neoplastic disease. In most patients 
with persistent or recurrent neoplastic disease, thyroglobulin concentration will increase 
dramatically during hypothyroidism following withdrawal of thyroid hormone treatment.  
If there is histologically confirmed thyroid cancer, then 6-8 weeks after thyroidectomy the 
patient is admitted for radioiodine thyroablation. The patient comes in a fully developed 
deep clinical hypothyroidism (TSH level usually above 100 mU/l). To achieve sufficient 
accumulation of radioiodine in the thyroid remnants it is needed to be TSH higher than 30 
mU/l. Then we perform ablation of thyroid remnant by radioiodine, which in addition to 
destruction of the remaining thyroid tissue removed also possible intrathyroidal metastases. 
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After radioiodine therapy the suppressive therapy is started. 6 to 12 months after ablation 
the control whole-body scintigraphy is performed in hypothyroidism after 4 weeks 
withdrawal of thyroid hormones. 
In the postoperative monitoring of patients with differentiated thyroid cancer should be 
solved a serious problem that is disturbing the patient life. This is hypothyroidism, which is 
a prerequisite for the implementation of thyroablation, whole body radioiodine scintigraphy 
and any further RAIT. It must be deep enough, which can be in actively working patients 
after withdrawal of suppressive therapy considerable difficult. Fortunately the rapid tumor 
growth is rarely stimulated by a brief rise in TSH concentration. The usual scheme is to 
carry out the treatment or control of patients during hospitalization after discontinuation of 
levothyroxine replacement for approximately 4-5 weeks. This has lead to profound 
hypothyroidism. In a small number of patients on long-term suppressive therapy we have 
observed only a moderate response to TSH after withdrawal of T4. Another option is to 
combine T4 and triiodothyronine (T3). Short-term administration of T3 alleviates some of 
the symptoms of prolonged hypothyroidism and must be stopped 2 weeks before 
radioiodine administration. This procedure also achieves a corresponding increase in TSH 
levels and hypothyroid patients subjectively perceived better. The third option is 
administration of recombinant human thyrotropin (rhTSH - Thyrogen) which stimulates 
thyroid tissue without requiring the discontinuation of thyroid hormone therapy. rhTSH 
can be used for diagnostic purposes (determination of thyroglobulin, scintigraphy) and 
before RAIT. Thyrogen should be used in patients who are either unable to mount an 
adequate endogenous TSH response to thyroid hormone withdrawal or in whom 
withdrawal is medically contraindicated. The use of Thyrogen allows for radioiodine 
imaging while the patient are euthyroid on levothyroxine. The clearance of radioiodine is 
approximately 50% greater in euthyroid patients than in hypothyroid patients, who have 
decreased renal function. Thus, radioiodine retention is less in euthyroid patients at the time 
of imaging and this factor should be considered when selecting the activity of radioiodine 
for imaging. Thyrotropin also stimulates the production of thyroglobulin and increases the 
usefulness of this tumour marker in patients treated with thyroid hormone who have had 
thyroid tissue ablated. For its high price Thyrogen unfortunately cannot be used in all 
patients with thyroid cancer. 
Suppression of endogenous secretion of TSH should be always maintained in patients with 
differentiated thyroid cancer. In low risk patients considered as cured, the levothyroxine 
dose is modified to maintain a low but detectable serum TSH concentration (0,1 to 0,5 
mU/l). In high risk patients with persistent/recurrent disease and even those considered as 
cured, higher doses of levothyroxine are continued, with the objective of attaining a serum 
TSH level of 0,1 mU/l or less, the free triiodothyronine concentration should be maintained 
within the normal range to avoid any significant overdosage. Reduction of serum 
thyroglobulin concentration is achieved with doses of thyroid hormone that reduce serum 
TSH to very low levels. 
5. Conclusion 
This chapter describes treatment options for some kinds of benign thyroid disease and 
differentiated thyroid cancers with radioactive iodine and context of this therapy with the 
development of post-radiation  hypothyroidism. Moreover, deliberately induced 
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hypothyroidism by thyroablation and in the further course also by the withdrawal of 
substitution and suppressive thyroid hormone therapy is used in the diagnosis and 
treatment of differentiated thyroid carcinomas. 
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